<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Premature adrenarche</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Premature adrenarche</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Premature adrenarche</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Selma F Witchel, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Rosenfield, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mitchell E Geffner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Adrenarche refers to the progressive maturation of the adrenal cortex that normally becomes manifest after five years of age and is associated with an increased serum dehydroepiandrosterone sulfate (DHEAS) level. Pubarche is the physical manifestation of adrenarche and is characterized by the development of pubic hair, axillary hair, adult apocrine body odor, acne, and increased oiliness of hair and skin.</p><p>Pubarche is considered premature if it develops before age eight years in girls and nine years in boys. Premature adrenarche, indicated by a premature elevation of DHEAS levels, is the most common cause of premature pubarche. Premature adrenarche is considered to be a variant of normal development. Premature adrenarche is a diagnosis of exclusion; other causes of pubarche need to be contemplated and excluded. The differential diagnosis includes precocious puberty and other causes of hyperandrogenemia and virilization.</p><p>The clinical presentation, evaluation, and differential diagnosis of premature pubarche and premature adrenarche are discussed below. Other UpToDate topic reviews with related information are:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5798.html" rel="external">"Physiology and clinical manifestations of normal adrenarche"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5849.html" rel="external">"Normal puberty"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5812.html" rel="external">"Definition, etiology, and evaluation of precocious puberty"</a>.)</p><p></p><p class="headingAnchor" id="H192200052"><span class="h1">DEFINITIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Premature pubarche</strong> – Premature pubarche is defined as the appearance of sexual pubic or axillary hair before age eight years in girls and age nine years in boys. Adult apocrine odor, mild acne, and increased oiliness of skin and hair may occur.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Premature adrenarche</strong> – Premature adrenarche is an idiopathic condition defined as premature pubarche <strong>plus</strong> the biochemical demonstration of an adrenal C19 steroid pattern indicative of adrenarche (typically defined as a dehydroepiandrosterone sulfate [DHEAS] concentration above 40 mcg/dL) before age eight years in girls and before nine years in boys (<a class="graphic graphic_table graphicRef75217" href="/d/graphic/75217.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. In addition to premature pubarche, oily skin or hair, acne (typically microcomedonal), and/or apocrine body odor may occur as clinical manifestations of premature adrenarche.</p><p></p><p class="bulletIndent1">Although premature adrenarche is typically considered to be a variation in normal maturation, the diagnosis requires exclusion of other causes of adrenal steroid elevations. The adrenarchal steroids are predominantly DHEAS and dehydroepiandrosterone (DHEA), their precursors, their metabolites, and, to a lesser extent, other androgenic steroids. These steroids are collectively referred to as "C19 steroids."</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Virilization </strong>– In children, mild virilization manifests as early-onset and/or slow progression of pubic/axillary hair development, acne, and/or hirsutism in both sexes. Moderate to severe virilization is associated with clitoromegaly in girls and penile enlargement in boys. In both sexes, moderate to severe virilization can be accompanied by rapid progression of pubic hair development, cystic acne, accelerated linear growth velocity, and increased muscle mass. Bone age radiographs typically show accelerated skeletal maturation. Bloodwork demonstrates elevated circulating androgen concentrations. Virilization that is present at birth reflects prenatal androgen exposure, which may not be reflected in laboratory tests on the infant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precocious puberty</strong> – Precocious puberty refers to precocious gonadarche with associated secondary sex characteristics, ie, breast development before age eight years in girls and testicular enlargement before age nine years in boys. It is usually due to increased gonadotropin-releasing hormone (GnRH) secretion, leading to increased pituitary gonadotropin secretion and gonadal sex steroid hormone secretion. This form of precocious puberty is also known as GnRH-dependent precocious puberty or central precocious puberty (CPP). (See  <a class="medical medical_review" href="/d/html/5812.html" rel="external">"Definition, etiology, and evaluation of precocious puberty"</a>.)</p><p></p><p class="headingAnchor" id="H3484020743"><span class="h1">EPIDEMIOLOGY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Typical timing of pubic hair development </strong>– Typical timing and pace of pubic hair development has been reported in several large studies (<a class="graphic graphic_table graphicRef141199" href="/d/graphic/141199.html" rel="external">table 2</a>) [<a href="#rid2">2-6</a>]. These data show differences in timing between populations and variance within each population studied. As an example, a study from Denmark [<a href="#rid4">4</a>] reported much later pubic hair development compared with studies from the United States [<a href="#rid5">5,6</a>]. Studies from the United States also report race- and ethnicity-related differences in onset of pubic hair development and other pubertal milestones. It is important to note that these differences in pubertal timing are smaller than the overall variation between individuals in the population. Clinical decisions should be based on an individual patient's characteristics and family history and less so on racial or ethnic background. (See  <a class="medical medical_review" href="/d/html/5849.html" rel="external">"Normal puberty", section on 'Typical pubertal timing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Premature pubarche</strong> – Premature pubic hair development (premature pubarche) is more common in girls than in boys; the ratio of affected girls to boys is 4:1 or higher [<a href="#rid7">7-9</a>].</p><p></p><p class="bulletIndent1">Premature pubarche is commonly encountered in pediatric practice. The Pediatric Research in Office Settings (PROS) study assessed pubertal development in over 17,000 healthy girls in the United States and Puerto Rico in the setting of a pediatric office practice. This cross-sectional study reported that pubic hair development was present in approximately 17 percent of Black girls and approximately 3 percent of White girls under eight years of age [<a href="#rid10">10</a>]. As reported in the PROS study involving 4131 boys, less than 5 percent of those under age nine years had pubic hair development [<a href="#rid11">11</a>]. These data should not be construed as prevalence data, due to the ascertainment bias of an office practice setting [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1">Premature pubarche is unusual before the age of four to five years but can rarely develop earlier [<a href="#rid7">7,12</a>]. Genital/scrotal hair has been described in girls and boys under two years of age. In some instances, this genital/scrotal hair has been associated with exposure to exogenous androgens or intense use of diaper rash prevention cream [<a href="#rid13">13</a>]; dehydroepiandrosterone sulfate (DHEAS) concentrations may be minimally elevated in these children but are typically less than 40 mcg/dL. Usually, the hair growth spontaneously resolves. Nevertheless, longitudinal follow-up is necessary to assess for additional signs of puberty [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1">Risk factors for premature adrenarche:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Obesity and evidence of insulin resistance have been identified in some but not all populations with premature adrenarche [<a href="#rid9">9,15-18</a>]. In some, insulin resistance is disproportionate to obesity [<a href="#rid15">15,19,20</a>]. In others, insulin resistance can be attributed to obesity [<a href="#rid17">17,21</a>]. How obesity and insulin resistance relate to premature adrenarche is unclear [<a href="#rid22">22</a>]. The molecular basis of the hyperinsulinemia and/or insulin resistance noted in children with premature adrenarche is poorly characterized and is likely to be multifactorial.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Low birth weight followed by early childhood adiposity rebound has been identified in several cohorts with premature pubarche [<a href="#rid23">23-25</a>], though not in others [<a href="#rid26">26-28</a>].</p><p></p><p class="headingAnchor" id="H1695112401"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>Premature adrenarche is considered a variation of normal development in which normal adrenarche occurs prematurely [<a href="#rid29">29</a>], which is linked to early maturation of the zona reticularis. At the onset of adrenarche, the 17,20-lyase activity of cytochrome P450c17 increases in conjunction with increased expression of cytochrome b5. Concurrently, expression of two enzymes, sulfotransferase 2A1 and 17-beta-hydrosteroid dehydrogenase type 5, increases, while expression of another enzyme, 3-beta-hydroxysteroid dehydrogenase, decreases. In addition, the enzyme 11-beta-hydroxylase type 1, encoded by <em>CYP11B1</em>, generates 11-beta-hydroxyandrostenedione.</p><p>The net result of these changes in enzyme expression leads to an increase in dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS), disproportionate to increases in androstenedione (<a class="graphic graphic_figure graphicRef58179" href="/d/graphic/58179.html" rel="external">figure 1</a>). In addition to DHEAS, there is increased secretion and concentrations of other circulating adrenal C19 steroid hormones, including androstenedione, testosterone, 11-beta-hydroxyandrostenedione, and 11-beta-hydroxytestosterone [<a href="#rid30">30</a>]. In peripheral tissues, these adrenal C19 steroids can be converted to other relevant C19 steroids including 11-ketoandrostenedione, 11-ketotestosterone, and, in some target tissues, 11-ketodihydrotestosterone. (See  <a class="medical medical_review" href="/d/html/5798.html" rel="external">"Physiology and clinical manifestations of normal adrenarche", section on 'Contribution of adrenarchal hormones to bioactive androgens'</a>.)</p><p>Excessive adrenal androgens cause the early onset of sexual hair in premature adrenarche. While DHEA and DHEAS have traditionally been considered to be "adrenal androgens," they do not bind to the androgen receptor and have minimal androgenic activity. The zona reticularis secretes 11-beta-hydroxyandrostenedione and 11-beta-hydroxytestosterone. These hormones undergo peripheral conversion to 11-ketoandrostendione and 11-ketotestosterone, respectively. Measurement of these hormones revealed that 11-ketotestosterone is the most abundant circulating bioactive C19 steroid during normal and premature adrenarche [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/d/html/5798.html" rel="external">"Physiology and clinical manifestations of normal adrenarche", section on 'Regulation of zona reticularis/adrenarchal growth, development, and function'</a>.)</p><p>Some retrospective studies have suggested that girls with premature adrenarche develop hyperandrogenism and hirsutism in adulthood. One small prospective study from Finland found decreased sex hormone-binding globulin (SHBG) concentrations and no increased prevalence of ovarian hyperandrogenism [<a href="#rid31">31</a>]. The data on obesity and insulin resistance are mixed, and there may be a slight increase in the prevalence of the mild polycystic ovary syndrome (PCOS) phenotypes that are related to infertility. (See <a class="local">'Potential adult risks of premature adrenarche'</a> below.)</p><p class="headingAnchor" id="H1369334143"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Pubarche is the primary clinical manifestation of adrenarche. Pubarche is characterized by the development of pubic hair or axillary hair. For girls, pubic hair usually begins on the labia majora and spreads onto the mons pubis. For boys, it usually begins at the base of the penis. Other signs of adrenarche such as adult apocrine body odor, acne, and increased oiliness of hair and skin may be present. In some instances, these other signs of androgen action may be the first manifestation of adrenarche [<a href="#rid9">9</a>]. When pubarche is due to premature adrenarche, other signs of secondary sexual development such as breast development, testicular enlargement, and virilization are absent.</p><p>Premature adrenarche is substantially more common in girls than in boys [<a href="#rid9">9</a>]. This sexual dimorphism occurs despite similar adrenarchal dehydroepiandrosterone sulfate (DHEAS) levels. Body fat is significantly higher in those with signs of premature adrenarche than in those without and has been speculated to modify peripheral androgen metabolism or action [<a href="#rid9">9</a>].</p><p>The specific features associated with premature adrenarche can vary. Stature, height velocity, and bone age may be increased but are usually within the normal ranges [<a href="#rid32">32-35</a>]. One-third of children with premature adrenarche have a bone age advanced by ≥2 years (see <a class="local">'Bone age radiograph'</a> below). This advancement is typically normal for height age, and predicted adult height and attained adult height are normal for mid-parental height [<a href="#rid29">29,36</a>]. This group has higher adrenarchal androgen (C19 steroid) levels and pubertal onset one to two years earlier compared with children with bone age within one year of chronologic age [<a href="#rid28">28,34</a>]. Some children have atypically high dehydroepiandrosterone (DHEA) responses to adrenocorticotropic hormone (ACTH) stimulation; this has been termed "exaggerated adrenarche" [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H17"><span class="h1">INITIAL EVALUATION OF PREMATURE PUBARCHE</span><span class="headingEndMark"> — </span>At a minimum, children with premature pubarche should be evaluated with a medical history including family history, physical examination, and bone age radiograph. Depending on these initial findings, additional studies may be indicated (<a class="graphic graphic_algorithm graphicRef131150" href="/d/graphic/131150.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H1637225054"><span class="h2">History and physical examination</span><span class="headingEndMark"> — </span>Evaluation of premature pubarche begins with a thorough medical history and physical examination.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>History</strong> – Relevant information includes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age at onset of the specific clinical features such as pubic hair development, axillary hair development, and acne.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tempo of pubertal maturation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Detailed family history, especially regarding ages of pubertal onset in the child's biologic parents and siblings, including age at menarche for women and age at voice breaking for men. A history of any endocrine or reproductive disorders should be ascertained.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Possible exogenous androgen exposure, eg, due to use of an androgen-containing cream, gel, or spray or oral anabolic body-building supplement by a caregiver. These androgens may be transferred to the child by skin-to-skin contact or inadvertent ingestion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physical examination</strong> – The physical examination should include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Accurate determinations of height and weight (anthropometric measurements) and comparison with previous growth parameters to assess for changes in linear growth velocity and rate of weight gain.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Focused evaluation for pubertal maturation, including sexual maturity rating (also known as Tanner staging) (<a class="graphic graphic_table graphicRef55329" href="/d/graphic/55329.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/d/html/5849.html" rel="external">"Normal puberty", section on 'Sexual maturity rating (Tanner stages)'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For girls, the extent of breast and pubic hair development should be ascertained. The external genitalia should also be examined for clitoromegaly and dulling of the vaginal mucosa. The presence of breast development suggests gonadotropin-releasing hormone (GnRH)-dependent precocious puberty rather than isolated premature adrenarche. Clitoromegaly suggests significant androgen exposure (virilization) such as would be observed with congenital adrenal hyperplasia (CAH).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For boys, testicular volume, phallic size, and pubic hair development should be assessed. Testicular and/or phallic enlargement is inconsistent with isolated premature adrenarche.</p><p></p><p class="bulletIndent1">For children with isolated pubarche without other secondary sex characteristics, these anthropometric measurements and sexual maturity rating provide baseline data to monitor pubertal progression. Children with additional secondary sexual characteristics require further evaluation for the possibility of disorders associated with precocious puberty or hyperandrogenism. (See  <a class="medical medical_review" href="/d/html/5812.html" rel="external">"Definition, etiology, and evaluation of precocious puberty"</a>.)</p><p></p><p class="headingAnchor" id="H704844984"><span class="h2">Bone age radiograph</span><span class="headingEndMark"> — </span>The evaluation for premature pubarche should include a bone age radiograph (<a class="graphic graphic_algorithm graphicRef131150" href="/d/graphic/131150.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Technique</strong> – The bone age is determined from a radiograph of the left hand and wrist. For the most commonly used Greulich and Pyle method, the bone age radiograph is compared with an atlas of radiographs from children of known ages. For the Tanner-Whitehouse 2 method, 20 different hand and wrist bones are scored. The bone age is a valuable indicator of the influence of sex steroids (estrogens and androgens) on epiphysial (growth plate) maturation. In addition to sex steroids, other hormones, obesity, genetics, nutritional status, various disease states, and certain medications can influence the tempo of epiphyseal maturation [<a href="#rid32">32,37</a>]. Bone age standards are largely based on hand and wrist radiographs from children of European ancestry from the 1930s to 60s [<a href="#rid38">38,39</a>]. Despite this shortcoming, a bone age radiograph is the single most important diagnostic test for the evaluation of premature pubarche because additional evaluation may be warranted for children with advanced bone maturation (defined as being ≥2 standard deviations (SD) above the child's chronologic age).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interpretation</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A normal or minimally advanced bone age (&lt;2 SD above the child's chronologic age) is found in most children with premature adrenarche. For the Greulich and Pyle method, tables are provided listing SD for each chronologic age and for height prediction for children ≥6 to 7 years old [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent2">Repeat bone age radiographs every 6 to 12 months may be useful to assess for accelerating skeletal maturation, prompting additional evaluation in children followed with the provisional diagnosis of isolated premature adrenarche. A follow-up bone age should be repeated if pubertal progression occurs or if height growth velocity accelerates. (See <a class="local">'Clinical follow-up'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Markedly advanced bone age (≥2 SD above the child's chronologic age) is found in some children with premature adrenarche. Finding an advanced bone age raises suspicion for other conditions and prompts additional laboratory tests. Laboratory testing is also indicated if the child has signs of virilization or pubertal development, regardless of bone age. (See <a class="local">'Laboratory tests'</a> below.)</p><p></p><p class="bulletIndent2">Some experts use bone age &gt;2 SD above the <strong>height age</strong> (rather than ≥2 SD above the child's chronologic age) as a threshold for moving on to laboratory testing. Calculating height age improves the specificity for distinguishing children with virilizing disorders from those with premature adrenarche and reduces the number of children that require laboratory testing. As an example, in a series of children with premature adrenarche, nearly 30 percent had bone age advancement of ≥2 years (equivalent to ≥2 SD at their average age of seven years) and 10 percent of these had bone age advancement of ≥3 years [<a href="#rid33">33</a>]<em>.</em> Those with ≥2 years bone age advancement were significantly taller by an average of 1.7 SD compared with those with &lt;1 year advanced bone age; they also had significantly higher body mass index (1.69 versus 1.07 SD) and higher dehydroepiandrosterone sulfate (DHEAS; 86 versus 63 mcg/dL), with normal testosterone and 17-hydroxyprogesterone (17OHP) levels.</p><p></p><p class="headingAnchor" id="H4104579819"><span class="h1">FURTHER EVALUATION FOR CHILDREN WITH ADVANCED BONE AGE</span></p><p class="headingAnchor" id="H2612308312"><span class="h2">Referral</span><span class="headingEndMark"> — </span>Children with premature pubarche and advanced bone age should be referred to a pediatric endocrinologist for the next part of the evaluation, if possible. Specialized expertise is generally needed to accurately interpret the bone age radiograph results, select the appropriate laboratory tests, ascertain whether additional imaging is needed, and determine benefits of medical intervention. The general approach implemented by the specialist is outlined below.</p><p>If the evaluation by the specialist determines that the premature pubarche is likely due to premature adrenarche, clinical follow-up can be performed by the specialist or the general pediatrician. (See <a class="local">'Follow-up'</a> below.)</p><p class="headingAnchor" id="H2298713097"><span class="h2">Laboratory tests</span><span class="headingEndMark"> — </span>Laboratory tests help distinguish between the diagnostic considerations and are essential for children with advanced bone age (≥2 standard deviations [SD]) and/or rapid height velocity. For practical considerations, the specialist may perform some laboratory testing regardless of bone age results because these results are helpful to reassure the parents regarding the diagnosis (<a class="graphic graphic_algorithm graphicRef131150" href="/d/graphic/131150.html" rel="external">algorithm 1</a>).</p><p>The panel of laboratory studies may include:</p><p class="bulletIndent1"><span class="glyph">●</span>Dehydroepiandrosterone sulfate (DHEAS)</p><p class="bulletIndent1"><span class="glyph">●</span>Testosterone</p><p class="bulletIndent1"><span class="glyph">●</span>Androstenedione</p><p class="bulletIndent1"><span class="glyph">●</span>17-hydroxyprogesterone (17OHP), obtained by 8:00 AM</p><p></p><p>If the physical examination reveals breast development or testicular enlargement, early morning luteinizing hormone (LH; ultrasensitive assay) and follicle-stimulating hormone levels should also be ascertained to assess for gonadotropin-releasing hormone (GnRH)-dependent precocious puberty (also known as central precocious puberty [CPP]).</p><p>In the past, steroid hormones had been determined using radioimmunoassays. Methods such as liquid chromatography-tandem mass spectrometry (LC-MS/MS) and gas chromatography-mass spectrometry (GC-MS) are now commonly utilized. LC-MS/MS and GC-MS provide greater specificity and sensitivity for many hormone determinations [<a href="#rid41">41</a>]. Values for cut-points listed in the following sections are based on normative data using radioimmunoassay results (<a class="graphic graphic_table graphicRef75217" href="/d/graphic/75217.html" rel="external">table 1</a>). Another table (<a class="graphic graphic_table graphicRef130205" href="/d/graphic/130205.html" rel="external">table 4</a>) lists median values and interquartile ranges measured by LC-MS/MS reported by one group of investigators. Results of these tests should be interpreted in view of the assay technique and the reference ranges for each hormone as established by the performing clinical laboratory.</p><p>Results are interpreted as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>DHEAS</strong> – Girls and boys with premature adrenarche typically have DHEAS concentrations of 40 to 115 mcg/dL (1.1 to 3.1 micromol/L) according to radioimmunoassay (of note, concentrations measured by LC-MS/MS are approximately 45 percent lower [<a href="#rid29">29</a>]). For patients with premature adrenarche, dehydroepiandrosterone (DHEA) and DHEAS concentrations are generally appropriate for the sexual maturity rating (Tanner stage) of pubic hair development. An extremely elevated DHEAS value may direct the diagnostic evaluation to assess for an adrenal androgen-secreting tumor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Testosterone and androstenedione</strong> – Girls and boys with premature adrenarche typically have testosterone levels ≤20 ng/dL (0.7 nmol/L) (<a class="graphic graphic_table graphicRef75217" href="/d/graphic/75217.html" rel="external">table 1</a>). Higher testosterone and/or androstenedione concentrations warrant additional evaluation for other disorders. Elevated androstenedione prompts consideration of congenital adrenal hyperplasia (CAH). For boys, elevated testosterone concentrations are noted in GnRH-dependent precocious puberty (CPP), androgen-secreting tumors, and familial male-limited precocious puberty due to activating variants in the LH receptor gene. Elevated testosterone concentrations suggest an androgen-secreting tumor. (See <a class="local">'Other hyperandrogenic causes of premature pubarche'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>17OHP</strong> – An early morning baseline measurement of 17OHP is a cost-effective screening test for CAH due to 21-hydroxylase deficiency. CAH is an autosomal recessive disorder characterized by a broad phenotypic spectrum, ranging from classical salt-losing and simple virilizing forms identified during infancy to nonclassic CAH (NCCAH) forms that present with symptoms due to excessive androgen production. A 17OHP level of &gt;200 ng/dL (&gt;6 nmol/L) obtained at 8:00 AM has ≥95 percent sensitivity and specificity for distinguishing CAH due to 21-hydroxylase deficiency from other causes of premature pubarche [<a href="#rid42">42-46</a>]. The early morning timing for this sample is important because 17OHP concentrations show diurnal variation, with the highest concentrations in the morning, similar to cortisol. When the blood sample is obtained in the afternoon, a normal 17OHP value does not exclude CAH. Values are reasonably comparable for the different assay techniques [<a href="#rid47">47</a>]. Nevertheless, it is important to know the normative reference ranges for the clinical laboratory.</p><p></p><p class="bulletIndent1">Results are interpreted as follows (<a class="graphic graphic_table graphicRef75217" href="/d/graphic/75217.html" rel="external">table 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Normal</strong> (&lt;115 ng/dL [3.5 nmol/L]) – This result excludes CAH with &gt;95 percent confidence. These patients should be followed clinically and retested if they have signs of progressive puberty.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mildly elevated</strong> (between 115 and 200 ng/dL [3.5 to 6 nmol/L]) – This result is atypical but consistent with premature adrenarche [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent2">The patient should be followed clinically (ie, for evidence of progressive puberty or virilization) to determine if further testing is indicated. If the bone age becomes accelerated or virilization develops, an adrenocorticotropic hormone (ACTH) stimulation test should be performed. (See <a class="local">'Additional testing for selected patients'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Moderately elevated</strong> (between 200 and 1000 ng/dL [6 to 30 nmol/L]) – Such values raise the possibility of CAH [<a href="#rid42">42,45,47</a>]. An <a class="drug drug_pediatric" data-topicid="13183" href="/d/drug information/13183.html" rel="external">ACTH stimulation test</a> is recommended and is necessary to confirm the diagnosis. (See <a class="local">'Additional testing for selected patients'</a> below.)</p><p></p><p class="bulletIndent2">An 8:00 AM 17OHP level &gt;200 ng/dL (&gt;6.0 nmol/L) measured by radioimmunoassay has approximately 98 percent sensitivity and 96 percent specificity for detecting CAH in children with premature pubarche and in adolescents [<a href="#rid42">42,45</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Very elevated</strong> (≥1000 ng/dL [30 nmol/L]) – This finding is considered to be diagnostic of CAH by evidence-based guidelines [<a href="#rid47">47,48</a>]. Although an <a class="drug drug_pediatric" data-topicid="13183" href="/d/drug information/13183.html" rel="external">ACTH stimulation test</a> is not required to make the diagnosis of CAH in such patients, it may be useful to determine if they are at risk for acute adrenal insufficiency. (See <a class="local">'ACTH stimulation test'</a> below.)</p><p></p><p class="headingAnchor" id="H2673050465"><span class="h2">Additional testing for selected patients</span></p><p class="headingAnchor" id="H4218295420"><span class="h3">ACTH stimulation test</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – Patients with a random 17OHP concentration ≥200 ng/dL (6 nmol/L), elevated DHEAS &gt;115 mcg/dL, and/or mild-moderately elevated androstenedione and/or testosterone levels should be further evaluated with an <a class="drug drug_pediatric" data-topicid="13183" href="/d/drug information/13183.html" rel="external">ACTH stimulation test</a> (<a class="graphic graphic_algorithm graphicRef131434" href="/d/graphic/131434.html" rel="external">algorithm 2</a>).</p><p></p><p class="bulletIndent1">An <a class="drug drug_pediatric" data-topicid="13183" href="/d/drug information/13183.html" rel="external">ACTH stimulation test</a> is the definitive test to assess for 21-hydroxyase deficiency and other disorders of adrenal steroidogenesis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Technique</strong> – To perform the <a class="drug drug_pediatric" data-topicid="13183" href="/d/drug information/13183.html" rel="external">ACTH stimulation test</a>, an early morning baseline blood sample for steroid hormone measurements is obtained, followed immediately by administration of the ACTH (cosyntropin, a synthetic form of ACTH) 250 micrograms given intravenously or intramuscularly. A second blood sample is obtained 30 or 60 minutes later.</p><p></p><p class="bulletIndent1">In addition to measuring basal and stimulated 17OHP, cortisol levels are measured to assess adrenocortical cortisol reserve. Other hormones including 17-hydroxypregnenolone, DHEA, androstenedione, 11-deoxycortisol, and progesterone can be measured to assess for uncommon types of CAH.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interpretation</strong> – The peak serum 17OHP response after ACTH stimulation can be interpreted as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Normal stimulated 17OHP values (eg, peak &lt;335 ng/dL [10 nmol/L]) virtually exclude CAH due to 21-hydroxylase deficiency (<a class="graphic graphic_table graphicRef75217" href="/d/graphic/75217.html" rel="external">table 1</a>). If the child has concerning symptoms (markedly advanced bone age or virilization), he or she should be further evaluated to exclude other types of CAH or an androgen-secreting tumor.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intermediate stimulated 17OHP values (eg, peak ≥335 to 999 ng/dL [10 to 30 nmol/L]) are found in carriers for 21-hydroxylase deficiency or in some uncommon types of CAH. When the ACTH-stimulated 17OHP peak value falls within this range, genetic testing is necessary to confirm a definitive diagnosis of heterozygosity for 21-hydroxylase deficiency or another type of CAH [<a href="#rid46">46,48</a>]. Slightly abnormal values for adrenal androgens and their precursors may be found in other genetic disorders affecting the hypothalamic-pituitary-gonadal axis. (See <a class="local">'Other hyperandrogenic causes of premature pubarche'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A serum 17OHP peak response ≥1000 ng/dL (30 nmol/L) is considered to be diagnostic of CAH due to 21-hydroxylase deficiency by evidence-based clinical guidelines [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cortisol</strong> – While the ACTH-stimulated cortisol response may be used to assess the adrenal response to stress, the risk for acute adrenal insufficiency is extremely low in individuals with untreated NCCAH [<a href="#rid48">48</a>]. Using newer LC-MS/MS assays, an ACTH-stimulated cortisol response &gt;14 mcg/dL (386 nmol/L) indicates normal adrenal cortisol reserve [<a href="#rid47">47,49,50</a>]. Conversely, an ACTH-stimulated cortisol response below this threshold suggests that supplemental glucocorticoid doses may be beneficial under conditions of physiologic stress (eg, high fever, acute gastroenteritis).</p><p></p><p class="bulletIndent1">Among individuals with NCCAH receiving glucocorticoid replacement therapy, the highest risk for acute adrenal insufficiency occurs when glucocorticoid replacement therapy is withdrawn abruptly.</p><p></p><p class="headingAnchor" id="H2734947143"><span class="h3">Dexamethasone suppression test</span><span class="headingEndMark"> — </span>The possibility of an androgen-secreting tumor is raised by any of the following [<a href="#rid51">51</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Severe or rapid virilization</p><p class="bulletIndent1"><span class="glyph">●</span>Significantly advanced bone age</p><p class="bulletIndent1"><span class="glyph">●</span>Markedly elevated DHEAS (eg, &gt;5 times the age-specific upper limit of normal)</p><p class="bulletIndent1"><span class="glyph">●</span>Moderately elevated testosterone or androstenedione (eg, &gt;2 times the age-specific upper limit of normal)</p><p></p><p>If Cushing syndrome is suspected, a <a class="drug drug_pediatric" data-topicid="13214" href="/d/drug information/13214.html" rel="external">dexamethasone</a> suppression test may be informative as a screening test (<a class="graphic graphic_algorithm graphicRef131436" href="/d/graphic/131436.html" rel="external">algorithm 3</a>). An overnight low-dose dexamethasone suppression test is helpful to screen for Cushing syndrome [<a href="#rid29">29</a>]. Results can be interpreted as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>If <a class="drug drug_pediatric" data-topicid="13214" href="/d/drug information/13214.html" rel="external">dexamethasone</a> suppresses cortisol (morning cortisol &lt;1.8 mcg/dL), Cushing syndrome is unlikely</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If <a class="drug drug_pediatric" data-topicid="13214" href="/d/drug information/13214.html" rel="external">dexamethasone</a> fails to suppress cortisol (morning cortisol ≥1.8 mcg/dL), evaluation for Cushing syndrome is warranted</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If <a class="drug drug_pediatric" data-topicid="13214" href="/d/drug information/13214.html" rel="external">dexamethasone</a> fails to suppress C19 steroid concentrations (DHEAS, androstenedione, and testosterone), evaluation for an androgen-secreting tumor should be performed (see <a class="local">'Imaging studies'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In some instances, longer <a class="drug drug_pediatric" data-topicid="13214" href="/d/drug information/13214.html" rel="external">dexamethasone</a> suppression tests may be indicated, eg, dosing for 48 hours (see  <a class="medical medical_review" href="/d/html/151.html" rel="external">"Establishing the diagnosis of Cushing syndrome"</a>)</p><p></p><p class="headingAnchor" id="H2299561427"><span class="h3">Imaging studies</span><span class="headingEndMark"> — </span>Ultrasonography is often the initial imaging modality to discern among adrenal, testicular, and ovarian tumors.</p><p class="bulletIndent1"><span class="glyph">●</span>The possibility of an adrenocortical tumor is raised by the presence of marked virilization, significantly advanced skeletal maturation, and markedly elevated DHEAS concentrations. Hyperandrogenism (with or without hypercortisolism) should be confirmed by laboratory testing before proceeding to imaging studies.</p><p></p><p class="bulletIndent1">Adrenal ultrasound is typically the first imaging test. However, ultrasound may fail to identify adrenal tumors smaller than 3 cm. Computed tomography scans can identify smaller lesions and are useful because of speed and high spatial resolution [<a href="#rid52">52</a>]. Magnetic resonance imaging offers several advantages including absence of ionizing radiation and better tissue differentiation [<a href="#rid53">53</a>]. Consultation with a radiologist may help to select the optimal imaging approach.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ovarian tumors may also present with marked virilization and advanced skeletal maturation, but DHEAS levels are generally not elevated in childhood in these rare tumors. For suspected ovarian tumors, initial imaging is with pelvic ultrasound. Transvaginal ultrasound studies should be avoided in young girls.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The possibility of a testicular tumor is raised by virilization in a young boy, with phallic enlargement and, often, testicular asymmetry. In boys with testicular tumors, LH and DHEAS are low (prepubertal) and testosterone is elevated. The initial imaging modality of choice is scrotal ultrasound [<a href="#rid54">54</a>].</p><p></p><p class="headingAnchor" id="H4035134726"><span class="h3">Genotyping</span><span class="headingEndMark"> — </span>The diagnosis of 21-hydroxylase deficiency is generally based on the ACTH-stimulated 17OHP response. However, genotyping may be helpful for genetic counseling and family planning [<a href="#rid47">47,48</a>].</p><p class="headingAnchor" id="H1991912132"><span class="h1">DIAGNOSIS OF PREMATURE ADRENARCHE</span><span class="headingEndMark"> — </span>Premature adrenarche is suspected when a child presents with isolated pubic and/or axillary hair before age eight years in girls and age nine years in boys. Premature adrenarche is a diagnosis of exclusion.</p><p>The diagnosis of premature adrenarche is likely if a focused evaluation finds:</p><p class="bulletIndent1"><span class="glyph">●</span>No evidence of other secondary sex characteristics (eg, breast development or testicular enlargement)</p><p class="bulletIndent1"><span class="glyph">●</span>Typical prepubertal external genitalia</p><p class="bulletIndent1"><span class="glyph">●</span>Slow tempo for progression of pubarche</p><p class="bulletIndent1"><span class="glyph">●</span>Normal height velocity</p><p class="bulletIndent1"><span class="glyph">●</span>Bone age is normal or advanced proportionate to height age</p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory tests (if performed):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dehydroepiandrosterone sulfate (DHEAS) concentration that is consistent with sexual maturity rating (also known as Tanner stage) for the extent of pubic hair development. Children with premature adrenarche typically have DHEAS concentrations between 40 and 115 mcg/dL (1.1 and 3.1 micromol/L) when measured by radioimmunoassay and somewhat lower concentrations when measured by LC-MS/MS. (See <a class="local">'Laboratory tests'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Testosterone and androstenedione are normal or minimally elevated for age and consistent with sexual maturity rating.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>17-hydroxyprogesterone (17OHP) concentration at 8:00 AM &lt;200 ng/dL (6 nmol/L).</p><p></p><p>Children failing to fulfill these criteria and/or have other findings may require further evaluation to determine the cause of the premature pubarche. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H140549385"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of premature pubarche includes other benign variants and several pathologic causes. The most common disorder is nonclassic congenital adrenal hyperplasia (NCCAH) (<a class="graphic graphic_table graphicRef130220" href="/d/graphic/130220.html" rel="external">table 5</a>).</p><p class="headingAnchor" id="H1819602276"><span class="h2">Variants of pubarche</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Idiopathic premature pubarche</strong> – This diagnosis is made when premature sexual hair is associated with a bone age that is normal for chronologic age and adrenal C19 steroid concentrations (eg, dehydroepiandrosterone sulfate [DHEAS]) are normal for preadrenarchal children. These findings distinguish this condition from premature adrenarche, in which DHEAS concentrations are mildly increased (<a class="graphic graphic_table graphicRef75217" href="/d/graphic/75217.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1">Transient pubic or scrotal hair development may rarely occur in children less than one year of age; growth velocity, hormone concentrations, and bone age radiograph results are normal for chronologic age [<a href="#rid1">1,14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypertrichosis</strong> – Hypertrichosis refers to excessive generalized, fine vellus body hair that occurs in both sexual and nonsexual areas. The consistency of the vellus hair is similar to that of forearm hair. This is a common clinical diagnostic problem because this type of hair can be difficult to distinguish from early stage 2 pubic hair. Therefore, if a child's pubic hair stage is indistinct and there is no other clinical evidence of virilization, the best approach may be a watchful observation period to determine whether the pubic hair becomes coarser and extends over the mons pubis. Hypertrichosis can be familial, ethnic/genetic, or due to exposure to specific medications (such as <a class="drug drug_pediatric" data-topicid="12615" href="/d/drug information/12615.html" rel="external">minoxidil</a>, <a class="drug drug_pediatric" data-topicid="13224" href="/d/drug information/13224.html" rel="external">diazoxide</a>, and <a class="drug drug_pediatric" data-topicid="12702" href="/d/drug information/12702.html" rel="external">phenytoin</a>) [<a href="#rid55">55,56</a>]. Thyroid disorders, anorexia nervosa or other forms of malnutrition, and porphyria can be associated with hypertrichosis [<a href="#rid56">56-58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exaggerated adrenarche</strong> – The term "exaggerated adrenarche" has been variously applied but is used here to indicate a clinically extreme type of premature adrenarche [<a href="#rid1">1</a>]. This variant is suggested in children with premature adrenarche who have features that suggest an atypical degree of androgen excess, particularly those with 17-hydroxypregnenolone responses to adrenocorticotropic hormone (ACTH) substantially above those typical of premature adrenarche (up to approximately 3000 ng/dL) (<a class="graphic graphic_table graphicRef75217" href="/d/graphic/75217.html" rel="external">table 1</a>). This diagnosis should only be considered only when virilizing disorders have been excluded.</p><p></p><p class="headingAnchor" id="H1481577096"><span class="h2">Other hyperandrogenic causes of premature pubarche</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Virilizing forms of CAHs</strong> – The virilizing forms of CAH can present with premature pubarche. These autosomal recessive disorders are associated with impaired cortisol secretion, increased ACTH secretion, and excessive adrenal C19 steroid hormone secretion. Phenotypes range from salt-losing to simple virilizing to nonclassic forms. Newborn girls with severe forms of CAH present with atypical genital appearance.</p><p></p><p class="bulletIndent1">The most common form of CAH is 21-hydroxylase deficiency due to pathogenic variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F613815&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz6YKg1a%2FW4UWnUoungvL68G&amp;TOPIC_ID=5806" target="_blank"><i>CYP21A2</i></a> gene, which can cause classic (salt-losing or simple virilizing) CAH or NCCAH (mild or late onset) [<a href="#rid59">59,60</a>]. Children with classic CAH (both salt-losing and simple virilizing forms) typically develop virilizing signs and symptoms prior to four years of age if untreated. Children with NCCAH typically present after age four years with premature pubarche or during adolescence with hirsutism and irregular menses. The clinical features of NCCAH cannot be reliably distinguished from those of isolated premature adrenarche [<a href="#rid48">48,61,62</a>]. NCCAH is common, with prevalence ranging from 1 in 200 to 1 in 1000 [<a href="#rid63">63</a>]. Additional features may include tall stature, accelerated linear growth velocity, advanced skeletal maturation, and phallic enlargement (penile enlargement or clitoromegaly).</p><p></p><p class="bulletIndent1">Uncommon forms of virilizing CAH may be caused by 3-beta-hydroxysteroid dehydrogenase type 2 deficiency (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F613890&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz5oKjeJqC3WAvESkV%2BKrJFz&amp;TOPIC_ID=5806" target="_blank"><i>HSD3B2</i></a> gene) or 11-beta-hydroxylase deficiency (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F610613&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz7nKcANu%2FKoJjf%2BXbeNO%2FG5&amp;TOPIC_ID=5806" target="_blank"><i>CYP11B1</i></a> gene) [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1">The diagnosis of CAH or NCCAH should be suspected in children with elevated unstimulated morning 17-hydroxyprogesterone (17OHP) levels (≥200 ng/dL [6.0 nmol/L]) [<a href="#rid42">42,45</a>] and is confirmed by a very elevated 17OHP level at baseline or in response to ACTH stimulation (≥1000 ng/dL [30 nmol/L]) [<a href="#rid47">47</a>]. Intermediate ACTH-stimulated 17OHP values (approximately 335 to 999 ng/dL) may be found in heterozygous carriers of 21-hydroxylase variants [<a href="#rid65">65,66</a>] or CAH due pathogenic variants in <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F613890&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz5oKjeJqC3WAvESkV%2BKrJFz&amp;TOPIC_ID=5806" target="_blank"><i>HSD3B2</i></a> [<a href="#rid67">67,68</a>] or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F610613&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz7nKcANu%2FKoJjf%2BXbeNO%2FG5&amp;TOPIC_ID=5806" target="_blank"><i>CYP11B1</i></a> [<a href="#rid64">64,69</a>]. Genetic confirmation may be necessary to confirm a definitive diagnosis of NCCAH [<a href="#rid46">46,48</a>]. (See <a class="local">'Additional testing for selected patients'</a> above.)</p><p></p><p class="bulletIndent1">Additional details regarding the diagnosis and management of the various forms of CAH are discussed in separate topic reviews. (See  <a class="medical medical_review" href="/d/html/147.html" rel="external">"Diagnosis and treatment of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency"</a> and  <a class="medical medical_review" href="/d/html/145.html" rel="external">"Clinical manifestations and diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children"</a> and  <a class="medical medical_review" href="/d/html/5800.html" rel="external">"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children"</a> and  <a class="medical medical_review" href="/d/html/15686.html" rel="external">"Uncommon congenital adrenal hyperplasias"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rare congenital disorders</strong> <strong>of steroid metabolism</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cortisone reductase deficiency (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F614662&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz43ydXO%2BBFFkE%2BFa2sLBgPF&amp;TOPIC_ID=5806" target="_blank">MIM #614662</a>) is a rare cause of premature pubarche. It is due to autosomal dominant variants of the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F600713&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoQJfDVW5yR7imlp9Iv0hjY&amp;TOPIC_ID=5806" target="_blank"><i>HSD11B1</i></a><em> </em>gene that have a dominant negative impact on gene activity in the heterozygous state. "Apparent" cortisone reductase deficiency (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F604931&amp;token=87jLzclRwWxNoI%2BQq5Gg7wgczl1AMvJ5ogOVhDtQa2EJiJ%2F2GGPbr2qDdZa8MySi&amp;TOPIC_ID=5806" target="_blank">MIM #604931</a>, also known as cortisone reductase deficiency type 1) is a rare autosomal recessive cause of premature pubarche associated with pathogenic variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F138090&amp;token=tEpDslnpc0F0kICl%2Fz7sFakATHRTAlgxtyC0kXeRiumc18g7fY3774DqjYsDwINd&amp;TOPIC_ID=5806" target="_blank"><i>H6PD</i></a> gene. Both disorders may present clinically with hyperandrogenism, manifesting as premature pubarche or with oligomenorrhea, acne, and hirsutism (similar to NCCAH). These disorders share a common mechanism: Both impair the oxidoreduction of cortisone to cortisol, resulting in shorter cortisol half-life and upregulation of ACTH secretion, leading to increased cortisol and adrenal C19 steroid secretion [<a href="#rid70">70</a>]. (See  <a class="medical medical_review" href="/d/html/15686.html" rel="external">"Uncommon congenital adrenal hyperplasias", section on 'Hexose-6-phosphate-dehydrogenase deficiency (apparent cortisone reductase deficiency)'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Apparent dehydroepiandrosterone (DHEA) sulfotransferase deficiency is caused by loss-of-function variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F603005&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdypWF07LH%2B7h0wQaPJljlm%2BS&amp;TOPIC_ID=5806" target="_blank"><i>PAPSS2</i></a> gene. These pathogenic variants impair the conversion of DHEA to DHEAS, resulting in uniformly low DHEAS concentrations. Premature pubarche and elevated C19 adrenal steroids can occur associated with increased DHEA levels. The phenotype includes androgen excess with or without bone dysplasia. (See  <a class="medical medical_review" href="/d/html/15686.html" rel="external">"Uncommon congenital adrenal hyperplasias", section on 'PAPSS2 deficiency (apparent DHEA sulfotransferase deficiency)'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Familial glucocorticoid resistance (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F615962&amp;token=87jLzclRwWxNoI%2BQq5Gg72db5zs3Sn9L7piPmfRMayxTEiyjQ9Lib5zMcGa57qSw&amp;TOPIC_ID=5806" target="_blank">MIM #615962</a>) is also known as generalized glucocorticoid resistance or Chrousos syndrome. This autosomal dominant disorder, due to pathogenic variants of the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F138040&amp;token=tEpDslnpc0F0kICl%2Fz7sFakATHRTAlgxtyC0kXeRiumtWUo8j5jcDSo0kB%2FAvksa&amp;TOPIC_ID=5806" target="_blank"><i>NR3C1</i></a><em> </em>gene (that encodes the glucocorticoid receptor), is a rare cause of premature pubarche [<a href="#rid71">71,72</a>]. These variants impair glucocorticoid signaling, resulting in glucocorticoid resistance, loss of negative feedback inhibition, and increased ACTH secretion, leading to compensatory increased cortisol concentrations. Increased ACTH secretion also amplifies mineralocorticoid and adrenal C19 steroid secretion. Characteristic features include fatigue, acne, premature pubarche, irregular menses, infertility, hypertension, hypokalemia, and metabolic alkalosis [<a href="#rid73">73</a>]. Despite elevated cortisol concentrations, affected individuals generally do not have the physical stigmata typical of Cushing syndrome. Diagnostic evaluation includes assessment of two to three consecutive days of urinary free cortisol determinations. In addition, serial overnight <a class="drug drug_pediatric" data-topicid="13214" href="/d/drug information/13214.html" rel="external">dexamethasone</a> suppression tests can be performed. Treatment consists of a high-dose, mineralocorticoid-sparing glucocorticoid such as dexamethasone. (See  <a class="medical medical_review" href="/d/html/5848.html" rel="external">"The child with tall stature and/or abnormally rapid growth", section on 'Uncommon endocrine causes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cushing syndrome</strong> – Cushing syndrome refers to states of glucocorticoid excess. In children, the most common cause of Cushing syndrome is exogeneous glucocorticoid treatment. Cushing disease refers to excessive pituitary ACTH secretion, typically due to a pituitary corticotroph adenoma, and is an extremely rare cause of premature pubarche. Other causes of Cushing syndrome include adrenal tumors, bilateral micronodular adrenal hyperplasia, primary bilateral macronodular adrenocortical hyperplasia, and ectopic ACTH secretion. Like Cushing disease, these disorders may be associated with hyperandrogenism. Diagnostic features of Cushing syndrome include elevated late-night salivary cortisol concentrations and failure to suppress cortisol and ACTH during an overnight <a class="drug drug_pediatric" data-topicid="13214" href="/d/drug information/13214.html" rel="external">dexamethasone</a> suppression test (25 mcg/kg, maximum dose 1 mg) [<a href="#rid74">74,75</a>]. (See <a class="local">'Dexamethasone suppression test'</a> above and  <a class="medical medical_review" href="/d/html/125.html" rel="external">"Causes and pathophysiology of Cushing syndrome", section on 'Cushing disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Androgen-secreting tumors</strong> – Adrenal or gonadal androgen-secreting tumors are extremely rare causes of premature pubarche. Typically, the tempo of pubertal changes is rapid; linear growth velocity and skeletal maturation are accelerated. Androgen-secreting tumors can arise in the adrenal cortex, testicular Leydig cell, or ovary [<a href="#rid76">76</a>]. Their characteristic features and initial evaluation are discussed briefly below and in more detail separately. (See  <a class="medical medical_review" href="/d/html/5812.html" rel="external">"Definition, etiology, and evaluation of precocious puberty", section on 'Causes of peripheral precocity'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adrenocortical androgen-secreting tumors are rare and tend to occur in children under five years of age. These tumors usually present with virilization and accelerated skeletal maturation. Although clinical features suggesting hypercortisolism may be inconsistent, most tumors are also associated with hypercortisolism [<a href="#rid53">53</a>]. DHEAS concentration are extremely elevated in over 90 percent of patients [<a href="#rid54">54</a>]. The adrenal tumors can be adenomas or carcinomas.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gonadal androgen-secreting tumors are rare. Boys with testicular Leydig cell tumors may present with premature pubarche; phallic enlargement and testicular asymmetry may be present. Ovarian androgen-secreting tumors are usually Sertoli-Leydig cells tumors; girls may develop clitoromegaly [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tumors that secrete beta-human chorionic gonadotropin (beta-hCG) can develop in the liver, brain, or testes. When these occur in boys, the beta-hCG can stimulate testicular luteinizing hormone (LH) receptors, leading to increased testosterone secretion; in girls, the presence of tumor-produced beta-hCG rarely causes precocious puberty.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Central precocious puberty (CPP)</strong> – Gonadotropin-releasing hormone (GnRH)-dependent precocious puberty, also known as CPP, refers to the premature reactivation of the normally quiescent hypothalamic-pituitary-gonadal axis of early childhood. CPP can usually be distinguished from premature adrenarche because breast development in girls or testicular enlargement in boys is present; these clinical findings associated with CPP typically precede the development of pubic hair. However, isolated pubarche can occasionally be the first sign of CPP in girls or boys [<a href="#rid78">78</a>]. Typically, CPP progresses over time with variable tempos. Secondary CPP can occur in patients with advanced skeletal maturation associated with CAH or adrenal tumors, usually after initiation of treatment [<a href="#rid79">79</a>]. (See  <a class="medical medical_review" href="/d/html/5812.html" rel="external">"Definition, etiology, and evaluation of precocious puberty"</a>.)</p><p></p><p>Other causes of precocious puberty are discussed separately. (See  <a class="medical medical_review" href="/d/html/5812.html" rel="external">"Definition, etiology, and evaluation of precocious puberty", section on 'Causes of peripheral precocity'</a>.)</p><p class="headingAnchor" id="H67009238"><span class="h1">FOLLOW-UP</span></p><p class="headingAnchor" id="H820542281"><span class="h2">Counseling</span><span class="headingEndMark"> — </span>Premature adrenarche is an idiopathic condition that does not require any specific endocrine treatment. Counseling to patients and their parents or caregivers may include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Premature adrenarche can usually be considered as a variation of normal development. The child can be told that this is a normal event that started a bit early. If the child is uncomfortable with pubic or axillary hairs despite reassurance, the hairs can be trimmed with small scissors. If body odor is upsetting to the child or parent, deodorant can be used sparingly. A hypoallergenic deodorant is preferable to an antiperspirant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Premature adrenarche is distinct from central precocious puberty (CPP). Families can be reassured that puberty/menses are not imminent. However, children with premature adrenarche typically begin central puberty (indicated by breast development or testicular enlargement) one to two years earlier than average [<a href="#rid28">28,80</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The exact underlying basis for normal adrenarche remains unclear. Premature adrenarche is thought to be due to early onset of the normal maturation of the adrenal zona reticularis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some children have idiopathic premature pubarche, which may be due to unusual sensitivity of their hair follicles to normal trace amounts of C19 steroid hormones.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children with premature adrenarche may have a slightly increased risk for insulin resistance and obesity in adulthood [<a href="#rid29">29</a>]. To minimize risks for insulin resistance and other potential adult disorders, the best strategy involves helping the child maintain a healthy body weight, practice healthy eating habits, and engage in regular exercise. (See <a class="local">'Potential adult risks of premature adrenarche'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some girls with premature adrenarche may develop polycystic ovary syndrome (PCOS) during late adolescence or adulthood. However, the risk of developing PCOS appears to be low, based on limited longitudinal data. (See <a class="local">'Potential adult risks of premature adrenarche'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Girls with premature pubarche due to premature adrenarche may be at risk for anxiety, depression, and eating disorders. A long-term follow-up study reported significantly higher scores on psychological tests for these symptoms in early adulthood (average age 21 years) [<a href="#rid81">81</a>]. Like other early maturing children, they should be considered a psychologically vulnerable population [<a href="#rid82">82</a>].</p><p></p><p class="headingAnchor" id="H2275270453"><span class="h2">Clinical follow-up</span><span class="headingEndMark"> — </span>Children diagnosed with premature adrenarche or premature pubarche should be followed clinically with serial physical examinations (eg, every 6 to 12 months) to monitor for the possibility of precocious puberty or a virilizing disorder. If symptoms do not progress and height velocity remains normal, these children can be reassessed less frequently. The bone age examination can be repeated approximately 6 to 12 months after initial presentation or sooner if the symptoms progress. Laboratory studies may be repeated if symptoms progress.</p><p class="headingAnchor" id="H710848450"><span class="h2">Potential adult risks of premature adrenarche</span><span class="headingEndMark"> — </span>The increased prevalence of obesity and evidence of insulin resistance in individuals with premature adrenarche have raised concern about risk for related health problems during adulthood. A retrospective study published in 1993 suggested that premature pubarche/adrenarche was often followed by ovarian hyperandrogenism [<a href="#rid83">83</a>]. Subsequent studies have shown varying results regarding progression from premature adrenarche to ovarian hyperandrogenism [<a href="#rid31">31,81,84,85</a>]. The data regarding obesity and insulin resistance are mixed. Limited available data suggest that the prevalence of mild PCOS phenotypes might be slightly increased. For now, longitudinal follow-up and endorsement of healthy lifestyle choices are prudent therapeutic strategies.</p><p class="headingAnchor" id="H3188929890"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/117619.html" rel="external">"Society guideline links: Normal puberty and puberty-related disorders"</a>.)</p><p class="headingAnchor" id="H11142039"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/16739.html" rel="external">"Patient education: Early puberty (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H25"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions</strong> – Premature pubarche is the isolated appearance of sexual hair prior to age eight years in girls and nine years in boys. Premature adrenarche is the most common cause of premature pubarche (often accompanied by seborrhea, axillary hair, microcomedonal acne, and/or adult body odor) and is characterized by increased adrenal steroid C19 secretion by the zona reticularis. The predominant adrenal C19 steroid hormones are dehydroepiandrosterone sulfate (DHEAS) and dehydroepiandrosterone (DHEA). (See <a class="local">'Definitions'</a> above and <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Premature pubarche is more common in girls than in boys. It is seen in up to 15 percent of girls in a primary care setting in the United States, but the prevalence varies between populations and subpopulations (<a class="graphic graphic_table graphicRef141199" href="/d/graphic/141199.html" rel="external">table 2</a>). (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Premature adrenarche is a diagnosis of exclusion.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial evaluation</strong> – The evaluation includes a focused history and physical examination, looking for evidence of rapid skeletal growth or other secondary sex characteristics, and obtaining a bone age radiograph (<a class="graphic graphic_algorithm graphicRef131150" href="/d/graphic/131150.html" rel="external">algorithm 1</a>). Children with advanced bone age should be further evaluated with a panel of endocrine tests, including DHEAS, testosterone, androstenedione, and 17-hydroxyprogesterone (17OHP). (See <a class="local">'Initial evaluation of premature pubarche'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Additional testing</strong> – Selected children may require further testing with an adrenocorticotropic hormone (ACTH) stimulation test or <a class="drug drug_pediatric" data-topicid="13214" href="/d/drug information/13214.html" rel="external">dexamethasone</a> suppression test if indicated (<a class="graphic graphic_algorithm graphicRef131434" href="/d/graphic/131434.html" rel="external">algorithm 2</a> and <a class="graphic graphic_algorithm graphicRef131436" href="/d/graphic/131436.html" rel="external">algorithm 3</a>). (See <a class="local">'Additional testing for selected patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of premature adrenarche is confirmed if a focused evaluation finds isolated pubarche with no evidence of other secondary sex characteristics (ie, breast development or testicular enlargement), typical prepubertal external genitalia, slow progression, normal height velocity, and normal or minimally advanced bone age. DHEAS (if measured) is typically between 40 to 115 mcg/dL (1.1 to 3.1 micromol/L), and other laboratory tests are normal for the child’s sexual maturity rating (also known as Tanner stage) (<a class="graphic graphic_table graphicRef75217" href="/d/graphic/75217.html" rel="external">table 1</a>). (See <a class="local">'Diagnosis of premature adrenarche'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis of premature adrenarche includes idiopathic premature pubarche, gonadotropin-releasing hormone (GnRH)-dependent precocious puberty, congenital adrenal hyperplasia (CAH; especially the nonclassic form of 21-hydroxylase deficiency), and rare congenital disorders or tumors associated with clinical features or biochemical evidence of hyperandrogenism (<a class="graphic graphic_table graphicRef130220" href="/d/graphic/130220.html" rel="external">table 5</a>). (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow up</strong> – For most children, premature pubarche (whether associated with premature adrenarche or not) can be considered as a benign variation of normal development. These children should be followed clinically with serial physical examinations (eg, initially every six months) to monitor for the possibility of precocious puberty or hyperandrogenism. If there is minimal progression of symptoms and growth velocity remains normal, these children can be reassessed at longer intervals thereafter. (See <a class="local">'Follow-up'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rosenfield RL. Clinical review: Identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92:787.</a></li><li><a class="nounderline abstract_t">Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969; 44:291.</a></li><li><a class="nounderline abstract_t">Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970; 45:13.</a></li><li><a class="nounderline abstract_t">Juul A, Teilmann G, Scheike T, et al. Pubertal development in Danish children: comparison of recent European and US data. Int J Androl 2006; 29:247.</a></li><li><a class="nounderline abstract_t">Rosenfield RL, Lipton RB, Drum ML. Thelarche, pubarche, and menarche attainment in children with normal and elevated body mass index. Pediatrics 2009; 123:84.</a></li><li><a class="nounderline abstract_t">Susman EJ, Houts RM, Steinberg L, et al. Longitudinal development of secondary sexual characteristics in girls and boys between ages 91/2 and 151/2 years. Arch Pediatr Adolesc Med 2010; 164:166.</a></li><li><a class="nounderline abstract_t">Charkaluk ML, Trivin C, Brauner R. Premature pubarche as an indicator of how body weight influences the onset of adrenarche. Eur J Pediatr 2004; 163:89.</a></li><li><a class="nounderline abstract_t">Williams RM, Ward CE, Hughes IA. Premature adrenarche. Arch Dis Child 2012; 97:250.</a></li><li><a class="nounderline abstract_t">Mäntyselkä A, Jääskeläinen J, Lindi V, et al. The presentation of adrenarche is sexually dimorphic and modified by body adiposity. J Clin Endocrinol Metab 2014; 99:3889.</a></li><li><a class="nounderline abstract_t">Herman-Giddens ME, Slora EJ, Wasserman RC, et al. Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings network. Pediatrics 1997; 99:505.</a></li><li><a class="nounderline abstract_t">Herman-Giddens ME, Steffes J, Harris D, et al. Secondary sexual characteristics in boys: data from the Pediatric Research in Office Settings Network. Pediatrics 2012; 130:e1058.</a></li><li><a class="nounderline abstract_t">Kaplowitz P, Soldin SJ. Steroid profiles in serum by liquid chromatography-tandem mass spectrometry in infants with genital hair. J Pediatr Endocrinol Metab 2007; 20:597.</a></li><li><a class="nounderline abstract_t">Ramos CO, Macedo DB, Bachega TASS, et al. Premature Pubarche due to Exogenous Testosterone Gel or Intense Diaper Rash Prevention Cream Use: A Case Series. Horm Res Paediatr 2019; 91:411.</a></li><li><a class="nounderline abstract_t">Nebesio TD, Eugster EA. Pubic hair of infancy: endocrinopathy or enigma? Pediatrics 2006; 117:951.</a></li><li><a class="nounderline abstract_t">Denburg MR, Silfen ME, Manibo AM, et al. Insulin sensitivity and the insulin-like growth factor system in prepubertal boys with premature adrenarche. J Clin Endocrinol Metab 2002; 87:5604.</a></li><li><a class="nounderline abstract_t">Kaya G, Yavas Abali Z, Bas F, et al. Body mass index at the presentation of premature adrenarche is associated with components of metabolic syndrome at puberty. Eur J Pediatr 2018; 177:1593.</a></li><li><a class="nounderline abstract_t">Williams KM, Oberfield SE, Zhang C, et al. The Relationship of Metabolic Syndrome and Body Composition in Children with Premature Adrenarche: Is It Age Related? Horm Res Paediatr 2015; 84:401.</a></li><li><a class="nounderline abstract_t">Idkowiak J, Lavery GG, Dhir V, et al. Premature adrenarche: novel lessons from early onset androgen excess. Eur J Endocrinol 2011; 165:189.</a></li><li><a class="nounderline abstract_t">Oppenheimer E, Linder B, DiMartino-Nardi J. Decreased insulin sensitivity in prepubertal girls with premature adrenarche and acanthosis nigricans. J Clin Endocrinol Metab 1995; 80:614.</a></li><li><a class="nounderline abstract_t">Teixeira RJ, Ginzbarg D, Rodrigues Freitas J, et al. Serum leptin levels in premature pubarche and prepubertal girls with and without obesity. J Pediatr Endocrinol Metab 2004; 17:1393.</a></li><li><a class="nounderline abstract_t">Utriainen P, Jääskeläinen J, Romppanen J, Voutilainen R. Childhood metabolic syndrome and its components in premature adrenarche. J Clin Endocrinol Metab 2007; 92:4282.</a></li><li><a class="nounderline abstract_t">Rosenfield RL. Evidence that idiopathic functional adrenal hyperandrogenism is caused by dysregulation of adrenal steroidogenesis and that hyperinsulinemia may be involved. J Clin Endocrinol Metab 1996; 81:878.</a></li><li><a class="nounderline abstract_t">Ibáñez L, Valls C, Potau N, et al. Polycystic ovary syndrome after precocious pubarche: ontogeny of the low-birthweight effect. Clin Endocrinol (Oxf) 2001; 55:667.</a></li><li><a class="nounderline abstract_t">Cavarzere P, Mauro M, Gaudino R, et al. Role of Body Weight in the Onset and the Progression of Idiopathic Premature Pubarche. Horm Res Paediatr 2020; 93:351.</a></li><li><a class="nounderline abstract_t">Utriainen P, Laakso S, Liimatta J, et al. Premature adrenarche--a common condition with variable presentation. Horm Res Paediatr 2015; 83:221.</a></li><li><a class="nounderline abstract_t">Boonstra VH, Mulder PG, de Jong FH, Hokken-Koelega AC. Serum dehydroepiandrosterone sulfate levels and pubarche in short children born small for gestational age before and during growth hormone treatment. J Clin Endocrinol Metab 2004; 89:712.</a></li><li><a class="nounderline abstract_t">von Oettingen J, Sola Pou J, Levitsky LL, Misra M. Clinical presentation of children with premature adrenarche. Clin Pediatr (Phila) 2012; 51:1140.</a></li><li><a class="nounderline abstract_t">Liimatta J, Utriainen P, Voutilainen R, Jääskeläinen J. Girls with a History of Premature Adrenarche Have Advanced Growth and Pubertal Development at the Age of 12 Years. Front Endocrinol (Lausanne) 2017; 8:291.</a></li><li><a class="nounderline abstract_t">Rosenfield RL. Normal and Premature Adrenarche. Endocr Rev 2021; 42:783.</a></li><li><a class="nounderline abstract_t">Rege J, Turcu AF, Kasa-Vubu JZ, et al. 11-Ketotestosterone Is the Dominant Circulating Bioactive Androgen During Normal and Premature Adrenarche. J Clin Endocrinol Metab 2018; 103:4589.</a></li><li><a class="nounderline abstract_t">Tennilä J, Jääskeläinen J, Utriainen P, et al. PCOS Features and Steroid Profiles Among Young Adult Women with a History of Premature Adrenarche. J Clin Endocrinol Metab 2021; 106:e3335.</a></li><li><a class="nounderline abstract_t">Sopher AB, Jean AM, Zwany SK, et al. Bone age advancement in prepubertal children with obesity and premature adrenarche: possible potentiating factors. Obesity (Silver Spring) 2011; 19:1259.</a></li><li><a class="nounderline abstract_t">DeSalvo DJ, Mehra R, Vaidyanathan P, Kaplowitz PB. In children with premature adrenarche, bone age advancement by 2 or more years is common and generally benign. J Pediatr Endocrinol Metab 2013; 26:215.</a></li><li><a class="nounderline abstract_t">Oron T, Lebenthal Y, de Vries L, et al. Interrelationship of extent of precocious adrenarche in appropriate for gestational age girls with clinical outcome. J Pediatr 2012; 160:308.</a></li><li><a class="nounderline abstract_t">Voutilainen R, Jääskeläinen J. Premature adrenarche: etiology, clinical findings, and consequences. J Steroid Biochem Mol Biol 2015; 145:226.</a></li><li><a class="nounderline abstract_t">Mejorado-Molano FJ, Sanz-Calvo ML, Posada-Ayala A, et al. Adult Height in Girls With Idiopathic Premature Adrenarche: A Cohort Study and Design of a Predictive Model. Front Endocrinol (Lausanne) 2022; 13:852422.</a></li><li><a class="nounderline abstract_t">Klein KO, Newfield RS, Hassink SG. Bone maturation along the spectrum from normal weight to obesity: a complex interplay of sex, growth factors and weight gain. J Pediatr Endocrinol Metab 2016; 29:311.</a></li><li class="breakAll">Greulich WW, Pyle SI. Radiographic Atlas of Skeletal Development of the Hand and Wrist, 2nd ed, Stanford University Press, 1999.</li><li class="breakAll">Tanner JM, Whitehouse RH, Cameron N, et al. Assessment of Skeletal Maturity and Prediction of Adult Height (TW2 Method), 2nd end, Goldstein H (Ed), Academic Press, 1983.</li><li class="breakAll">Gruelich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist, Stanford University Press, Palo Alto, CA 1959.</li><li><a class="nounderline abstract_t">Handelsman DJ. Mass spectrometry, immunoassay and valid steroid measurements in reproductive medicine and science. Hum Reprod 2017; 32:1147.</a></li><li><a class="nounderline abstract_t">Armengaud JB, Charkaluk ML, Trivin C, et al. Precocious pubarche: distinguishing late-onset congenital adrenal hyperplasia from premature adrenarche. J Clin Endocrinol Metab 2009; 94:2835.</a></li><li><a class="nounderline abstract_t">Bidet M, Bellanné-Chantelot C, Galand-Portier MB, et al. Clinical and molecular characterization of a cohort of 161 unrelated women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency and 330 family members. J Clin Endocrinol Metab 2009; 94:1570.</a></li><li><a class="nounderline abstract_t">Livadas S, Dracopoulou M, Dastamani A, et al. The spectrum of clinical, hormonal and molecular findings in 280 individuals with nonclassical congenital adrenal hyperplasia caused by mutations of the CYP21A2 gene. Clin Endocrinol (Oxf) 2015; 82:543.</a></li><li><a class="nounderline abstract_t">Chesover AD, Millar H, Sepiashvili L, et al. Screening for Nonclassic Congenital Adrenal Hyperplasia in the Era of Liquid Chromatography-Tandem Mass Spectrometry. J Endocr Soc 2020; 4:bvz030.</a></li><li><a class="nounderline abstract_t">Ambroziak U, Kępczyńska-Nyk A, Kuryłowicz A, et al. The diagnosis of nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, based on serum basal or post-ACTH stimulation 17-hydroxyprogesterone, can lead to false-positive diagnosis. Clin Endocrinol (Oxf) 2016; 84:23.</a></li><li><a class="nounderline abstract_t">Speiser PW, Arlt W, Auchus RJ, et al. Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2018; 103:4043.</a></li><li><a class="nounderline abstract_t">Carmina E, Dewailly D, Escobar-Morreale HF, et al. Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women. Hum Reprod Update 2017; 23:580.</a></li><li><a class="nounderline abstract_t">Ueland GÅ, Methlie P, Øksnes M, et al. The Short Cosyntropin Test Revisited: New Normal Reference Range Using LC-MS/MS. J Clin Endocrinol Metab 2018; 103:1696.</a></li><li><a class="nounderline abstract_t">Grassi G, Morelli V, Ceriotti F, et al. Minding the gap between cortisol levels measured with second-generation assays and current diagnostic thresholds for the diagnosis of adrenal insufficiency: a single-center experience. Hormones (Athens) 2020; 19:425.</a></li><li><a class="nounderline abstract_t">Idkowiak J, Elhassan YS, Mannion P, et al. Causes, patterns and severity of androgen excess in 487 consecutively recruited pre- and post-pubertal children. Eur J Endocrinol 2019; 180:213.</a></li><li><a class="nounderline abstract_t">Albano D, Agnello F, Midiri F, et al. Imaging features of adrenal masses. Insights Imaging 2019; 10:1.</a></li><li><a class="nounderline abstract_t">Pinto EM, Zambetti GP, Rodriguez-Galindo C. Pediatric adrenocortical tumours. Best Pract Res Clin Endocrinol Metab 2020; 34:101448.</a></li><li><a class="nounderline abstract_t">Sangüesa C, Veiga D, Llavador M, Serrano A. Testicular tumours in children: an approach to diagnosis and management with pathologic correlation. Insights Imaging 2020; 11:74.</a></li><li><a class="nounderline abstract_t">Rica Echevarría I, García Del Monte J, Delgado Rubio A, et al. Severe hypertrichosis in infants due to transdermic exposure to 5% and 7% topical minoxidil. Dermatol Ther 2020; 33:e14230.</a></li><li><a class="nounderline abstract_t">Aguayo-Orozco TA, Ríos-González BE, Castro-Martínez AG, et al. Generalized hypertrichosis syndromes in Mexico. Am J Med Genet C Semin Med Genet 2020; 184:1014.</a></li><li><a class="nounderline abstract_t">Ai J, Leonhardt JM, Heymann WR. Autoimmune thyroid diseases: etiology, pathogenesis, and dermatologic manifestations. J Am Acad Dermatol 2003; 48:641.</a></li><li><a class="nounderline abstract_t">Horner ME, Alikhan A, Tintle S, et al. Cutaneous porphyrias part I: epidemiology, pathogenesis, presentation, diagnosis, and histopathology. Int J Dermatol 2013; 52:1464.</a></li><li><a class="nounderline abstract_t">Witchel SF. Congenital Adrenal Hyperplasia. J Pediatr Adolesc Gynecol 2017; 30:520.</a></li><li><a class="nounderline abstract_t">Claahsen-van der Grinten HL, Speiser PW, Ahmed SF, et al. Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management. Endocr Rev 2022; 43:91.</a></li><li><a class="nounderline abstract_t">Dörr HG, Schulze N, Bettendorf M, et al. Genotype-phenotype correlations in children and adolescents with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Mol Cell Pediatr 2020; 7:8.</a></li><li><a class="nounderline abstract_t">Binay C, Simsek E, Cilingir O, et al. Prevalence of nonclassic congenital adrenal hyperplasia in Turkish children presenting with premature pubarche, hirsutism, or oligomenorrhoea. Int J Endocrinol 2014; 2014:768506.</a></li><li><a class="nounderline abstract_t">Hannah-Shmouni F, Morissette R, Sinaii N, et al. Revisiting the prevalence of nonclassic congenital adrenal hyperplasia in US Ashkenazi Jews and Caucasians. Genet Med 2017; 19:1276.</a></li><li><a class="nounderline abstract_t">Kandemir N, Yilmaz DY, Gonc EN, et al. Novel and prevalent CYP11B1 gene mutations in Turkish patients with 11-β hydroxylase deficiency. J Steroid Biochem Mol Biol 2017; 165:57.</a></li><li><a class="nounderline abstract_t">Witchel SF, Lee PA, Suda-Hartman M, Hoffman EP. Hyperandrogenism and manifesting heterozygotes for 21-hydroxylase deficiency. Biochem Mol Med 1997; 62:151.</a></li><li><a class="nounderline abstract_t">Admoni O, Israel S, Lavi I, et al. Hyperandrogenism in carriers of CYP21 mutations: the role of genotype. Clin Endocrinol (Oxf) 2006; 64:645.</a></li><li><a class="nounderline abstract_t">Lutfallah C, Wang W, Mason JI, et al. Newly proposed hormonal criteria via genotypic proof for type II 3beta-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab 2002; 87:2611.</a></li><li><a class="nounderline abstract_t">Mermejo LM, Elias LL, Marui S, et al. Refining hormonal diagnosis of type II 3beta-hydroxysteroid dehydrogenase deficiency in patients with premature pubarche and hirsutism based on HSD3B2 genotyping. J Clin Endocrinol Metab 2005; 90:1287.</a></li><li><a class="nounderline abstract_t">Joehrer K, Geley S, Strasser-Wozak EM, et al. CYP11B1 mutations causing non-classic adrenal hyperplasia due to 11 beta-hydroxylase deficiency. Hum Mol Genet 1997; 6:1829.</a></li><li><a class="nounderline abstract_t">White PC. Alterations of Cortisol Metabolism in Human Disorders. Horm Res Paediatr 2018; 89:320.</a></li><li><a class="nounderline abstract_t">Nicolaides NC, Charmandari E. Chrousos syndrome: from molecular pathogenesis to therapeutic management. Eur J Clin Invest 2015; 45:504.</a></li><li class="breakAll">Nicolaides NC, Kino T, Chrousos G, Charmandari E.. Endotext, Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Grossman A, Hershman JM, Hofland J, Kalra S, Kaltsas G, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, McGee EA, McLachlan R, Morley JE, New M, Purnell J, Sahay R, Singer F, Stratakis CA, Trence DL, Wilson DP. (Eds), MDText.com, Inc., South Dartmouth (MA) 2000.</li><li><a class="nounderline abstract_t">Charmandari E, Kino T, Ichijo T, Chrousos GP. Generalized glucocorticoid resistance: clinical aspects, molecular mechanisms, and implications of a rare genetic disorder. J Clin Endocrinol Metab 2008; 93:1563.</a></li><li><a class="nounderline abstract_t">Ferrigno R, Hasenmajer V, Caiulo S, et al. Paediatric Cushing's disease: Epidemiology, pathogenesis, clinical management and outcome. Rev Endocr Metab Disord 2021; 22:817.</a></li><li><a class="nounderline abstract_t">Ueland GÅ, Kellmann R, Jørstad Davidsen M, et al. Bedtime Salivary Cortisol as a Screening Test for Cushing Syndrome in Children. J Endocr Soc 2021; 5:bvab033.</a></li><li><a class="nounderline abstract_t">Schnuckle EM, Williamson A, Carpentieri D, Taylor S. Ovarian Sex Cord Stromal Tumor, Steroid Cell, NOS in an Adolescent: A Case Report. J Pediatr Adolesc Gynecol 2021; 34:94.</a></li><li><a class="nounderline abstract_t">Young RH, Scully RE. Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases. Am J Surg Pathol 1985; 9:543.</a></li><li><a class="nounderline abstract_t">Biro FM, Huang B, Daniels SR, Lucky AW. Pubarche as well as thelarche may be a marker for the onset of puberty. J Pediatr Adolesc Gynecol 2008; 21:323.</a></li><li><a class="nounderline abstract_t">Pescovitz OH, Comite F, Cassorla F, et al. True precocious puberty complicating congenital adrenal hyperplasia: treatment with a luteinizing hormone-releasing hormone analog. J Clin Endocrinol Metab 1984; 58:857.</a></li><li><a class="nounderline abstract_t">Ibáñez L, Dimartino-Nardi J, Potau N, Saenger P. Premature adrenarche--normal variant or forerunner of adult disease? Endocr Rev 2000; 21:671.</a></li><li><a class="nounderline abstract_t">Livadas S, Bothou C, Kanaka-Gantenbein C, et al. Unfavorable Hormonal and Psychologic Profile in Adult Women with a History of Premature Adrenarche and Pubarche, Compared to Women with Polycystic Ovary Syndrome. Horm Metab Res 2020; 52:179.</a></li><li><a class="nounderline abstract_t">Steinberg L, Morris AS. Adolescent development. Annu Rev Psychol 2001; 52:83.</a></li><li><a class="nounderline abstract_t">Ibañez L, Potau N, Virdis R, et al. Postpubertal outcome in girls diagnosed of premature pubarche during childhood: increased frequency of functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1993; 76:1599.</a></li><li><a class="nounderline abstract_t">Meas T, Chevenne D, Thibaud E, et al. Endocrine consequences of premature pubarche in post-pubertal Caucasian girls. Clin Endocrinol (Oxf) 2002; 57:101.</a></li><li><a class="nounderline abstract_t">Miller D, Emans SJ, Kohane I. Follow-up study of adolescent girls with a history of premature pubarche. J Adolesc Health 1996; 18:301.</a></li></ol></div><div id="topicVersionRevision">Topic 5806 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17179197" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical review: Identifying children at risk for polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5785179" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Variations in pattern of pubertal changes in girls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5440182" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Variations in the pattern of pubertal changes in boys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16466546" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pubertal development in Danish children: comparison of recent European and US data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19117864" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Thelarche, pubarche, and menarche attainment in children with normal and elevated body mass index.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20124146" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Longitudinal development of secondary sexual characteristics in girls and boys between ages 91/2 and 151/2 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14689304" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Premature pubarche as an indicator of how body weight influences the onset of adrenarche.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21835833" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Premature adrenarche.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25029425" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The presentation of adrenarche is sexually dimorphic and modified by body adiposity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9093289" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23085608" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Secondary sexual characteristics in boys: data from the Pediatric Research in Office Settings Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17642420" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Steroid profiles in serum by liquid chromatography-tandem mass spectrometry in infants with genital hair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30677757" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Premature Pubarche due to Exogenous Testosterone Gel or Intense Diaper Rash Prevention Cream Use: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16510682" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pubic hair of infancy: endocrinopathy or enigma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12466359" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Insulin sensitivity and the insulin-like growth factor system in prepubertal boys with premature adrenarche.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30056577" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Body mass index at the presentation of premature adrenarche is associated with components of metabolic syndrome at puberty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26513727" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The Relationship of Metabolic Syndrome and Body Composition in Children with Premature Adrenarche: Is It Age Related?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21622478" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Premature adrenarche: novel lessons from early onset androgen excess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7852529" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Decreased insulin sensitivity in prepubertal girls with premature adrenarche and acanthosis nigricans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15526717" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Serum leptin levels in premature pubarche and prepubertal girls with and without obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17698912" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Childhood metabolic syndrome and its components in premature adrenarche.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8772543" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Evidence that idiopathic functional adrenal hyperandrogenism is caused by dysregulation of adrenal steroidogenesis and that hyperinsulinemia may be involved.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11894979" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Polycystic ovary syndrome after precocious pubarche: ontogeny of the low-birthweight effect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33264767" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Role of Body Weight in the Onset and the Progression of Idiopathic Premature Pubarche.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25676474" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Premature adrenarche--a common condition with variable presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14764786" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Serum dehydroepiandrosterone sulfate levels and pubarche in short children born small for gestational age before and during growth hormone treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22893187" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Clinical presentation of children with premature adrenarche.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29163361" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Girls with a History of Premature Adrenarche Have Advanced Growth and Pubertal Development at the Age of 12 Years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33788946" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Normal and Premature Adrenarche.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30137510" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : 11-Ketotestosterone Is the Dominant Circulating Bioactive Androgen During Normal and Premature Adrenarche.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34060603" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : PCOS Features and Steroid Profiles Among Young Adult Women with a History of Premature Adrenarche.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21311512" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Bone age advancement in prepubertal children with obesity and premature adrenarche: possible potentiating factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23744298" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : In children with premature adrenarche, bone age advancement by 2 or more years is common and generally benign.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21907353" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Interrelationship of extent of precocious adrenarche in appropriate for gestational age girls with clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24923732" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Premature adrenarche: etiology, clinical findings, and consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35311244" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Adult Height in Girls With Idiopathic Premature Adrenarche: A Cohort Study and Design of a Predictive Model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26565541" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Bone maturation along the spectrum from normal weight to obesity: a complex interplay of sex, growth factors and weight gain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26565541" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Bone maturation along the spectrum from normal weight to obesity: a complex interplay of sex, growth factors and weight gain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26565541" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Bone maturation along the spectrum from normal weight to obesity: a complex interplay of sex, growth factors and weight gain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26565541" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Bone maturation along the spectrum from normal weight to obesity: a complex interplay of sex, growth factors and weight gain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28453777" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Mass spectrometry, immunoassay and valid steroid measurements in reproductive medicine and science.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19454583" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Precocious pubarche: distinguishing late-onset congenital adrenal hyperplasia from premature adrenarche.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19208730" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Clinical and molecular characterization of a cohort of 161 unrelated women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency and 330 family members.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25041270" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The spectrum of clinical, hormonal and molecular findings in 280 individuals with nonclassical congenital adrenal hyperplasia caused by mutations of the CYP21A2 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32110745" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Screening for Nonclassic Congenital Adrenal Hyperplasia in the Era of Liquid Chromatography-Tandem Mass Spectrometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26331608" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The diagnosis of nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, based on serum basal or post-ACTH stimulation 17-hydroxyprogesterone, can lead to false-positive diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30272171" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28582566" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29452421" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The Short Cosyntropin Test Revisited: New Normal Reference Range Using LC-MS/MS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32222957" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Minding the gap between cortisol levels measured with second-generation assays and current diagnostic thresholds for the diagnosis of adrenal insufficiency: a single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30566905" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Causes, patterns and severity of androgen excess in 487 consecutively recruited pre- and post-pubertal children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30684056" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Imaging features of adrenal masses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32636100" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Pediatric adrenocortical tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32462465" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Testicular tumours in children: an approach to diagnosis and management with pathologic correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32844481" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Severe hypertrichosis in infants due to transdermic exposure to 5% and 7% topical minoxidil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33283427" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Generalized hypertrichosis syndromes in Mexico.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12734493" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Autoimmune thyroid diseases: etiology, pathogenesis, and dermatologic manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24261722" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Cutaneous porphyrias part I: epidemiology, pathogenesis, presentation, diagnosis, and histopathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28450075" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Congenital Adrenal Hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33961029" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32647925" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Genotype-phenotype correlations in children and adolescents with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24778650" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Prevalence of nonclassic congenital adrenal hyperplasia in Turkish children presenting with premature pubarche, hirsutism, or oligomenorrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28541281" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Revisiting the prevalence of nonclassic congenital adrenal hyperplasia in US Ashkenazi Jews and Caucasians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26956189" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Novel and prevalent CYP11B1 gene mutations in Turkish patients with 11-βhydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9441866" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Hyperandrogenism and manifesting heterozygotes for 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16712666" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Hyperandrogenism in carriers of CYP21 mutations: the role of genotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12050224" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Newly proposed hormonal criteria via genotypic proof for type II 3beta-hydroxysteroid dehydrogenase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15585552" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Refining hormonal diagnosis of type II 3beta-hydroxysteroid dehydrogenase deficiency in patients with premature pubarche and hirsutism based on HSD3B2 genotyping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9302260" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : CYP11B1 mutations causing non-classic adrenal hyperplasia due to 11 beta-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29843121" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Alterations of Cortisol Metabolism in Human Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25715669" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Chrousos syndrome: from molecular pathogenesis to therapeutic management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25715669" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Chrousos syndrome: from molecular pathogenesis to therapeutic management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18319312" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Generalized glucocorticoid resistance: clinical aspects, molecular mechanisms, and implications of a rare genetic disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33515368" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Paediatric Cushing's disease: Epidemiology, pathogenesis, clinical management and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33928203" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Bedtime Salivary Cortisol as a Screening Test for Cushing Syndrome in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32781238" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Ovarian Sex Cord Stromal Tumor, Steroid Cell, NOS in an Adolescent: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3911780" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19064225" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Pubarche as well as thelarche may be a marker for the onset of puberty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6368580" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : True precocious puberty complicating congenital adrenal hyperplasia: treatment with a luteinizing hormone-releasing hormone analog.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11133068" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Premature adrenarche--normal variant or forerunner of adult disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32074632" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Unfavorable Hormonal and Psychologic Profile in Adult Women with a History of Premature Adrenarche and Pubarche, Compared to Women with Polycystic Ovary Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11148300" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Adolescent development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8501168" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Postpubertal outcome in girls diagnosed of premature pubarche during childhood: increased frequency of functional ovarian hyperandrogenism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12100077" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Endocrine consequences of premature pubarche in post-pubertal Caucasian girls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8860795" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Follow-up study of adolescent girls with a history of premature pubarche.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
